Hohorst HJ - Search Results

1

Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase alpha holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters.

Hohorst HJ, Bielicki L, Müller K, Voelcker G. Hohorst HJ, et al. J Cancer Res Clin Oncol. 1988;114(3):309-11. doi: 10.1007/BF00405840. J Cancer Res Clin Oncol. 1988. PMID: 3384844

2

Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.

Voelcker G, Pfeiffer B, Schnee A, Hohorst H. Voelcker G, et al. J Cancer Res Clin Oncol. 2000 Feb;126(2):74-8. J Cancer Res Clin Oncol. 2000. PMID: 10664245

3

Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.

Voelcker G, Bielicki L, Hohorst HJ. Voelcker G, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1997;123(11-12):623-31. doi: 10.1007/s004320050116. J Cancer Res Clin Oncol. 1997. PMID: 9620221

4

Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester.

Voelcker G, Hohorst HJ. Voelcker G, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1998;124(6):297-300. doi: 10.1007/s004320050172. J Cancer Res Clin Oncol. 1998. PMID: 9692835

5

Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.

Bielicki L, Voelcker G, Hohorst HJ. Bielicki L, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1984;107(3):195-8. doi: 10.1007/BF01032606. J Cancer Res Clin Oncol. 1984. PMID: 6736107

6

Synthesis of 1-aldofosfamide-perhydrothiazines.

Zimmermann J, Bauer HH, Hohorst HJ, Voelcker G. Zimmermann J, et al. Among authors: hohorst hj. Arzneimittelforschung. 2000 Sep;50(9):843-7. doi: 10.1055/s-0031-1300299. Arzneimittelforschung. 2000. PMID: 11050703

7

Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.

Bielicki L, Voelcker G, Hohorst HJ. Bielicki L, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1983;105(1):27-9. doi: 10.1007/BF00391828. J Cancer Res Clin Oncol. 1983. PMID: 6300134

8

[Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Wagner T, Heydrich D, Voelcker G, Hohorst HJ. Wagner T, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1980 Jan;96(1):79-92. doi: 10.1007/BF00412899. J Cancer Res Clin Oncol. 1980. PMID: 7358774 German.

9

[Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].

Voelcker G, Haeglsperger R, Hohorst HJ. Voelcker G, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1979 Apr 12;93(3):233-40. doi: 10.1007/BF00964578. J Cancer Res Clin Oncol. 1979. PMID: 468886 German.

10

Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ. Wagner T, et al. Among authors: hohorst hj. J Cancer Res Clin Oncol. 1981;100(1):95-104. doi: 10.1007/BF00405906. J Cancer Res Clin Oncol. 1981. PMID: 7240346

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters